Media Contacts

Kylene Metzger

Media Relations Specialist, Public Affairs

Jan 07, 2021 3:00 PM

Christy Mulder, RN, receives the second dose of the Pfizer/BioNTech vaccine on January 7, 2021

January 7, 2021 – University of Utah Health began administering the second dose of the Pfizer-BioNTech COVID-19 vaccine to frontline health care workers. Distribution of the second dose marks another milestone as U of U Health has vaccinated more than half of its health care personnel (HCP). “COVID-19 vaccinations have enabled us to protect our staff and continue providing the quality health care our community expects and deserves,” says Michael Good, MD, CEO of U of U Health.

The second dose of the Pfizer-BioNTech vaccine needs to be administered within 21-28 days after a patient receives the first dose. The second dose is needed for full protection against COVID-19. Vaccine recipients will likely experience side effects (injection site pain, muscle aches, chills, fever, headache, tiredness, etc.). This is the body’s reaction to boosting the immune system and a sign that the vaccine is working.

Due to vaccine availability, U of U Health care workers are being vaccinated in four waves. These HCP are prioritized based on their role on COVID-19 dedicated units and risk of exposure to COVID-19 in the workplace. The vaccine is offered through scheduled appointments to make the process more efficient and effective. Depending on supplies, U of U Health anticipates that all HCP will be offered the vaccine by the end of January.

Kavish Choudhary, PharmD, Christy Mulder, RN, and Tom Miller, MD, address the media about COVID-19 vaccine distribution. As many as 18,500 HCP, including clinical students, need to be vaccinated at U of U Health. To date, 59% of HCP have been vaccinated. “We are the fastest user of the vaccine in the state,” says Tom Miller, MD, CMO at U of U Health. “My thanks goes out to pharmacy, patient registration, and IT services for developing a system that allows us to rapidly inform the state of our vaccination rates, which has helped us stay at the front of the line in receiving the vaccine.”




coronavirus COVID-19 vaccine pfizer biontech